See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article for: SRPT
Sarepta Therapeutics Inc. (NASDAQ: SRPT), despite facing setbacks earlier this month with an FDA panel, is still going forward with its PDUFA date later this month (May 26). This has the potential to make or break Sarepta. The problem that it faced earlier was that Sarepta did not live up to FDA guidelines in this trial, and the company was ultimately questioned over it.
The FDA panel voted against recommending it for approval, although the patients within the trial pleaded for its recommendation. With that said, this PDUFA date will signal if these pleas were heard, and should the decision go one way or the other, we can expect a massive move within the stock.
Jefferies recently issued a mere $7 price target. Its research call in the first week of May said:
We see likely a new eteplirsen Phase 3 study would be required for approval and low probability of accelerated approval & 55% probability of positive Phase 3 data and launch by year-end of 2020 for eteplirsen in DMD… Eteplirsen should take meaningful market share given good safety profile if approved.
Shares of Sarepta closed Friday at $17.70, with a consensus analyst price target of $17.92 and a 52-week trading range of $8.00 to $41.97.
Source – 24/7 Wall St.
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Hot small cap stocks
small cap stock picks
FDA approval stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news